The frontline of TMA management
Thrombotic microangiopathy (TMA) is a pathological condition characterized by platelet thrombi-induced generalized microvascular occlusion, thrombocytopenia, and microangiopathic hemolytic anemia. TMA includes the life-threatening diseases thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS). TTP is different from HUS in that it has a severe deficiency in ADAMTS13 activity. Congenital TTP is caused by a lack of plasma ADAMTS13 activity caused by genetic mutations, and acquired TTP is caused by a secondary deficiency caused by autoantibodies. In Japan the only product approved for the treatment of congenital TTP is fresh frozen plasma containing ADAMTS13. Recombinant ADAMTS13 may provide a new treatment option for congenital TTP. The first-line treatment for acquired TTP is plasma exchange. Rituximab treatment should be considered for patients who are refractory or have relapsed. Caplacizumab is a nanobody that specifically targets von Willebrand factor. ISTH recently published guidelines recommending that caplacizumab be added to the initial treatment for acquired TTP. Atypical HUS (aHUS) is related with the dysregulation of the complement alternative pathway. Eculizumab, a monoclonal antibody that inhibits C5, was the first drug approved for aHUS, and it was found to be well-tolerated by patients and effective in clinical use. TMA is classified based on its etiology, and specific treatments for targeting various etiologies are now available.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
---|---|
Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 63(2022), 5 vom: 01., Seite 463-470 |
Sprache: |
Japanisch |
---|
Beteiligte Personen: |
Saito, Kenki [VerfasserIn] |
---|
Links: |
---|
Themen: |
ADAMTS13 |
---|
Anmerkungen: |
Date Completed 08.06.2022 Date Revised 08.06.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.11406/rinketsu.63.463 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM341840564 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM341840564 | ||
003 | DE-627 | ||
005 | 20231226012712.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||jpn c | ||
024 | 7 | |a 10.11406/rinketsu.63.463 |2 doi | |
028 | 5 | 2 | |a pubmed24n1139.xml |
035 | |a (DE-627)NLM341840564 | ||
035 | |a (NLM)35662172 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a jpn | ||
100 | 1 | |a Saito, Kenki |e verfasserin |4 aut | |
245 | 1 | 4 | |a The frontline of TMA management |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.06.2022 | ||
500 | |a Date Revised 08.06.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Thrombotic microangiopathy (TMA) is a pathological condition characterized by platelet thrombi-induced generalized microvascular occlusion, thrombocytopenia, and microangiopathic hemolytic anemia. TMA includes the life-threatening diseases thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS). TTP is different from HUS in that it has a severe deficiency in ADAMTS13 activity. Congenital TTP is caused by a lack of plasma ADAMTS13 activity caused by genetic mutations, and acquired TTP is caused by a secondary deficiency caused by autoantibodies. In Japan the only product approved for the treatment of congenital TTP is fresh frozen plasma containing ADAMTS13. Recombinant ADAMTS13 may provide a new treatment option for congenital TTP. The first-line treatment for acquired TTP is plasma exchange. Rituximab treatment should be considered for patients who are refractory or have relapsed. Caplacizumab is a nanobody that specifically targets von Willebrand factor. ISTH recently published guidelines recommending that caplacizumab be added to the initial treatment for acquired TTP. Atypical HUS (aHUS) is related with the dysregulation of the complement alternative pathway. Eculizumab, a monoclonal antibody that inhibits C5, was the first drug approved for aHUS, and it was found to be well-tolerated by patients and effective in clinical use. TMA is classified based on its etiology, and specific treatments for targeting various etiologies are now available | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ADAMTS13 | |
650 | 4 | |a Hemolytic-uremic syndrome | |
650 | 4 | |a Thrombotic thrombocytopenic purpura | |
650 | 4 | |a von Willebrand factor | |
650 | 7 | |a ADAMTS13 Protein |2 NLM | |
650 | 7 | |a EC 3.4.24.87 |2 NLM | |
700 | 1 | |a Matsumoto, Masanori |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 63(2022), 5 vom: 01., Seite 463-470 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
773 | 1 | 8 | |g volume:63 |g year:2022 |g number:5 |g day:01 |g pages:463-470 |
856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.63.463 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 63 |j 2022 |e 5 |b 01 |h 463-470 |